Orchid Pharma is currently trading at Rs 41.95, up by 4.60 points or 12.32% from its previous closing of Rs. 37.35 on the BSE.
The scrip opened at Rs. 38.30 and has touched a high and low of Rs. 42.70 and Rs. 37.40 respectively. So far 946693 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 75.30 on 06-Aug-2015 and a 52 week low of Rs. 32.60 on 29-Feb-2016.
Last one week high and low of the scrip stood at Rs. 40.35 and Rs. 35.40 respectively. The current market cap of the company is Rs. 375.43 crore.
The promoters holding in the company stood at 38.41% while Institutions and Non-Institutions held 5.39% and 52.41% respectively.
Orchid Pharma has received final approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Rasagiline Tablets 0.5 mg and 1 mg. This product is a FTF (First-to-file) application with a shared 180-day exclusivity for Orchid. Orchid expects to launch this product in Q4 of FY16-17.
Rasagiline Mesylate Tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. With a market size of over $ 300 million and limited generic competition, Orchid hopes to garner a decent market share from this product launch.